Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

Cellular Background

9

Phase 3 clinical trials (the last 8 of which have been successful)


We have run numerous large successful international Phase 3 clinical trials.


Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas including immunology, oncology, hematology, and dermatology.

Topical · Dermavant
VTAMA (Tapinarof)
Psoriasis
Commercialization
Topical · Dermavant
VTAMA (Tapinarof)
Atopic Dermatitis
Phase 3
Biologic · Immunovant
Batoclimab
Myasthenia Gravis
Phase 3
Biologic · Immunovant
Batoclimab
Thyroid Eye Disease
Phase 2
Biologic · Immunovant
Batoclimab
WAIHA
Phase 1
Biologic · Immunovant
Batoclimab
CIDP
Phase 1
Biologic · Immunovant
Batoclimab
Graves' Disease
Phase 1
Biologic · Immunovant
IMVT-1402
Numerous Indications
Small Molecule · Priovant
Brepocitinib
Dermatomyositis
Phase 3
Small Molecule · Priovant
Brepocitinib
Systemic Lupus Erythematosus
Phase 2
Small Molecule · Priovant
Brepocitinib
Other Indications
Phase 2
Biologic · New Vant
RVT-3101
Ulcerative Colitis
Phase 2
Biologic · New Vant
RVT-3101
Crohn's Disease
Phase 2
Biologic · Kinevant
Namilumab
Sarcoidosis
Phase 2
Small Molecule · Hemavant
RVT-2001
Transfusion Dependent Anemia in Patients with Lower-Risk MDs
Phase 1
Biologic · Affivant
AFVT-2101
Solid Tumors
Preclinical
Male Scientist in Lab
About Us

Interested in learning more?

Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

Our Companies
Our Companies

Nimble, entrepreneurial Vants

Explore our diverse family of biopharmaceutical and health technology companies.